NED
AMGN icon

Nancy E. Dempze’s Amgen AMGN Stock Holding History

Nancy E. Dempze’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$408K Sell
1,160
-100
-8% -$35.6K 0.22% 66
2025
Q4 		$412K Buy
+1,260
New +$400K 0.21% 71

Other funds holding AMGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Nancy E. Dempze's AMGN Position: Q1 2026 in Review

Nancy E. Dempze reduced its Amgen (AMGN) stake by 7.9% in Q1 2026, selling an estimated $35.6K and leaving 1,160 shares worth $408K. The position accounts for 0.22% of the portfolio, ranked #66.

Nancy E. Dempze first reported a position in AMGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $412K in Q4 2025. 3,130 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Nancy E. Dempze held 1,160 shares of Amgen worth $408K as of Q1 2026.
  • Nancy E. Dempze sold 100 Amgen shares in Q1 2026, an estimated $35.6K.
  • Amgen made up 0.22% of Nancy E. Dempze's portfolio in Q1 2026, its #66 holding.
  • Nancy E. Dempze first reported a position in Amgen in Q4 2025 and has held it in 2 quarters since.
  • Nancy E. Dempze's Amgen position peaked at $412K in Q4 2025.
  • 3,130 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Nancy E. Dempze's 13F filing for Q1 2026, filed 14 May 2026.